The clinically safe TRPV1 antagonist XEN-D0501 is currently under development as an oral drug for overactive bladder (148); undoubtedly, these findings provide valuable clinical data for the development of TRPV1-targeted drugs to treat obesity. The gene discussed is TRPV1; the disease is Obesity.